Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.

Purpose: To examine bevacizumab and ranibizumab utilization and disease monitoring patterns in patients with neovascular age-related macular degeneration (neovascular AMD) in clinical practice.

Design: Retrospective medical claims analysis.

Methods: Patients receiving ≥1 ranibizumab or bevacizumab injection during the 12 months after initial neovascular AMD diagnosis were included.